Can Cobalamin prevent Oxaliplatin induced peripheral neuropathy?

Naza Shakir Shareef  Shekhany; Jangi Shawkat  Salai

doi:10.56056/amj.2019.102

Authors

Naza Shakir Shareef Shekhany Department of pharmacology, college of pharmacy, Hawler medical university, Erbil, Iraq.
Jangi Shawkat Salai Department of Pharmacology and Biophysics, college of medicine, Hawler medical university, Erbil, Iraq.

DOI:

https://doi.org/10.56056/amj.2019.102

Keywords:

Oxaliplatin, Oxaliplatin-induced peripheral neuropathy, Vitamin B12

Abstract

Background and objectives:Peripheral neuropathy induced by oxaliplatin is one of the main reasons for discontinuing chemotherapy. In this article, we evaluated the role of vitamin B12 in the prevention of oxaliplatin-induced peripheral neuropathy.

Methods: A prospective randomized interventional study was done from 1st January 2018 to 30th De- cember 2018, in which patients who were diagnosed with gastrointestinal cancer in Rizgary and Nanakali teaching hospitals that have been scheduled to receive oxaliplatin-based regimen were enrolled. Patients were divided into two groups: control group received chemotherapy only and prophylaxis group received chemotherapy with vitamin B12; each group included fifteen patients with no significant differences between the groups regarding age and gender. The prophylaxis group received vitamin B12 injection in scheduled periods. All Patients received at least a cumulative dose of 500 mg/m2 of oxaliplatin. Patients were evaluated by nerve conduction study, B12 level, and other laboratory tests.

Results: Twenty-one patients completed the study. There was a significant decrease in the serum vitamin B12 level (601.84±398.43 to 363±337.31) post-chemotherapy among the control group. Among the prophylaxis group, the mean value of serum vitamin B12 increased significantly after chemotherapy. To summarize, there was a significant decrease in the amplitude of nerve conduction study in the control group as compared to the prophylaxis group espe- cially in left (11.85±6.84 to 8.14±5.36) and right (14.01±6.05 to 9.52±6.08) Sural nerves.

Conclusions:Vitamin B12 injection had an important role in the prevention of development of chronic oxaliplatin-induced peripheral neuropathy.

Downloads

Download data is not yet available.

References

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics: GLO- BOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018; 68(6): 394- 424.

De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16): 2938–47.

Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011; 18(1): 18–25.

Schmoll H, Cartwright T, Tabernero J, et al. Phase III trial of capecit- abine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007; 25(1): 102–9.

Faivre S, Chan D, Salinas R, et al. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol. 2003; 66(2): 225–37.

Todd RC, Lippard S.J. Inhibition of transcription by platinum antitu- mor compounds. Metallomics. 2009; 1(4): 280–91.

Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010; 29(4):482–91.

Argyriou A, Bruna J, Marmiroli P, et al. Chemotherapy-induced pe- ripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012; 82(1): 51–77.

Zedan A, Hansen T, Fex Svenningsen A, et al. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers. Clin Colorectal Cancer. 2014; 13(2): 73–80.

Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neuro- toxicity. Nat Rev Neurol. 2010; 6(12): 657–66.

Loprinzi C, Qin R, Dakhil S, et al. Phase III Randomized, Place- bo-Controlled, Double-Blind Study of Intravenous Calcium and Mag- nesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/ Alliance). JCO. 2013; 32(10): 997–1005.

De Andrade D, Teixeira M, Galhardoni R, et al. Pregabalin for the Prevention of Oxaliplatin?Induced Painful Neuropathy: A Randomized, Double?Blind Trial. The oncologist. 2017; 22(10): 1154-e105.

Zimmerman C, Atherton P, Pachman D, et al. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care in Cancer. 2016; 24(3): 1071–8.

Salehi Z, Roayaei M. Effect of Vitamin E on Oxaliplatin induced Pe- ripheral Neuropathy Prevention: A Randomized Controlled Trial. Interna- tional Journal of Preventive Medicine. 2015; 6 (1): 104.

Hershman D, Lacchetti C, Dworkin R, et al. Prevention and Manage- ment of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. JCO. 2014; 32(18):1 941–67.

Sun Y, Lai MS, Lu CJ. Effectiveness of vitamin B12 on diabetic neu- ropathy: systematic review of clinical controlled trials. Acta Neurologica Taiwanica. 2005; 14(2):48-54.

Zhang M, Han W, Hu S, et al. Methylcobalamin: a potential vitamin of pain killer. Neural Plasticity. 2013; 2013: 424651.

Schloss J, Colosimo M. B. vitamin complex and chemotherapy-in- duced peripheral neuropathy. Current Oncology Reports. 2017; 19 (12): 76.

Vidal?Alaball J, Butler C, Cannings?John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database of Systematic Reviews. 2005; (3):CD004655

Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. PAIN. 2009;144(3): 245-52.

Argyriou A, Polychronopoulos P, Iconomou G, et al. A review on ox- aliplatin-induced peripheral nerve damage. Cancer Treatment Reviews. 2008; 34(4):368-77.

Balayssac D, Ferrier J, Descoeur J, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opinion on Drug Safety. 2011; 10(3): 407–17.

Beijers A, Mols F, Vreugdenhil G. A systematic review on chronic ox- aliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care in Cancer. 2014; (7): 1999–2007.

Schloss J, Colosimo M, Airey C, et al. A randomised, placebo-con- trolled trial assessing the efficacy of an oral B group vitamin in prevent- ing the development of chemotherapy-induced peripheral neuropathy (CIPN). Support Care in Cancer. 2017;25(1): 195–204.

Schloss JM, Colosimo M, Airey C, et al. Chemotherapy-induced pe- ripheral neuropathy (CIPN) and vitamin B12 deficiency. Supportive Care in Cancer. 2015; 23(7): 1843–50.

Armstrong T, Almadrones L, Gilbert M. Chemotherapy-induced pe- ripheral neuropathy. In Oncology nursing forum 2005;32 (2):305-11 27.Vincenzi B, Frezza A, Schiavon G, et al. Identification of clinical pre- dictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care in Cancer. 2013; 21(5): 1313–9.

Grothey A. Oxaliplatin-safety profile: neurotoxicity. In Seminars in oncology 2003; 30 (4): 5-13.

Krishnan A, Goldstein D, Friedlander M, et al. Oxaliplatin?induced neurotoxicity and the development of neuropathy. Muscle & Nerve: Offi- cial Journal of the American Association of Electrodiagnostic Medicine. 2005;32 (1):51-60.

Green R. Vitamin B12 deficiency from the perspective of a practicing hematologist. Blood. 2017; 129(19): 2603–11.

Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supple- mentation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer. 2008; 123(6): 1227–39.

Jardim DL, Rodrigues CA, Novis YA. et al. Oxaliplatin-related throm- bocytopenia. Ann Oncol. 2012; 23(8): 1937–42.